VivoSim Labs, INC. (VIVS) stock
VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$0.12−0.00 (-2.91%)
Close on Nov 17, 2026Market cap $383.64KP/E –Yield –
VivoSim Labs gross margin
Gross margin is gross profit as a percentage of revenue.
VivoSim Labs's gross margin for the twelve months ending Mar 31, 2026 was 100.0%. For fiscal 2026 it was 100.0%, against 96.5% the year before. The highest annual figure on record is 100.0% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | 100.0% | +3.5 |
| FY2025 | Mar 31, 2025 | 96.5% | +10.2 |
| FY2020 | Mar 31, 2020 | 86.3% | +2.5 |
| FY2019 | Mar 31, 2019 | 83.8% | +5.5 |
| FY2018 | Mar 31, 2018 | 78.3% | +0.9 |
| FY2017 | Mar 31, 2017 | 77.4% | −22.6 |
| FY2016 | Mar 31, 2016 | 100.0% | +0.0 |
| FY2015 | Mar 31, 2015 | 100.0% | +12.5 |
| FY2011 | Dec 31, 2011 | 87.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | 100.0% | +0.0 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | 100.0% | +8.3 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | 100.0% | +3.3 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | 100.0% | +5.1 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | 100.0% | +0.0 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | 91.7% | −8.3 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | 96.7% | +1.0 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | 94.9% | +19.3 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | 100.0% | +15.0 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | 100.0% | +14.7 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | 95.6% | +8.5 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | 75.6% | −13.8 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | 85.0% | −0.5 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | 85.3% | +12.4 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | 87.2% | +4.5 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | 89.4% | +11.5 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | 85.5% | +15.8 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | 72.9% | −4.6 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | 82.7% | +1.1 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | 77.9% | +6.4 |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | 69.7% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | 77.5% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | 81.6% | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | 71.4% | – |
See a number that looks wrong?